Studies of visit-to-visit office blood pressure variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), a well-characterized cohort of participants randomized to intensive (<120 mm Hg) or standard (<140 mm Hg) systolic BP targets. We defined OBPV as the coefficient of variation of the systolic BP, using measurements taken during the 3-,6-, 9- and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV, while angiotensin converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no significant associations with the composite endpoint of fatal and non-fatal cardiovascular events (N=324 primary endpoints; adjusted hazard ratio [HR] 1.20, 95% confidence interval [CI] 0.85–1.69, highest versus lowest quintile), nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted HR 1.92, CI 1.22–3.03), although the association of OBPV overall with all-cause mortality was marginal (p=0.07). Our results suggest that clinicians should continue to focus on office BP control rather than on OBPV unless definitive benefits of reducing OBPV are shown in prospective trials.